Articles On Imugene (ASX:IMU)

Reporting from Sydney this morning, clinical-stage cancer immunotherapy developer Imugene [ASX:IMU] made the upbeat announcement that it now has a patent to treat patients in the US. A Notice of Allowance from the US Patent and Trademark Of...

The share market’s sparkling start to the year lost some of its fizz as the threat of higher interest rates dragged the Australian benchmark to its first losing week of 2023. The S&P/ASX 200 slid 56.6 points or 0.76 per cent this aft...

Shares fall to a three-week low amid RBA's 'hawkish' update. CBA says rate cut needed by end of year to avoid 'hard landing'. Allkem CFO dies of illness. Imugene soars on patent approval.

The share market slumped to a two-and-a-half week low as financial markets continued to adjust their expectations for the top of this interest rate cycle. The S&P/ASX 200 declined 51 points or 0.68 per cent by mid-session. The fall k...

ShareCafeASX down at noon despite RBA comments that inflation has likely peaked by Peter Milios   The Reserve Bank of Australia has revised its inflation forecasts, stating that the rapidly rising prices in the country have probably peaked....

ShareCafeStocks of the Hour: CZL, RGL, ALA                    Consolidated Zinc (ASX:CZL) has entered into a binding agreement with Impact Silver Corp. to sell its Plomosas Project in Mexico. In response, Brad Marwood, Executive Chair...

Highlights Imugene Limited has secured a Notice of Allowance relating a US patent application for its B-cell activating immunotherapy PD1-Vaxx. PD1-Vaxx is undergoing clinical development for non-small cell lung cancer. The patent tit...

The share price of S&P/ASX 200 Index (ASX: XJO) biopharmaceutical developer Imugene Limited (ASX: IMU) is soaring on Friday after the company announced a new United States patent. The patent relates to its B-cell activating immunothera...

Imugene (IMU) receives a Notice of Allowance from the US Patent and Trademark Office for its PD1-Vaxx technology The patent protects the composition of matter and method of treatment for PD1-Vaxx in cancer until 2038 PD1-Vaxx is a B-c...

The ASX will open lower on Friday after a Wall Street slump overnight Disney and Yahoo to lay off thousands of employees RBA expected to revise inflations forecasts today   The ASX is poised to open lower this morning as US stocks faded i...

The S&P/ASX 200 Index (ASX: XJO) posted its first gain of the week on Wednesday, lifting 0.35% to close at 7,530.1 points. It followed a strong session over on Wall Street. The Dow Jones Industrial Average Index (DJX: .DJI) rose 0.8% o...

ShareCafeASX closes 0.13% higher as Bitcoin spikes and China lifts coal ban by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.13 per cent higher at 7,511.6. Bitcoin hit its highest point since August due to investor interpret...

ShareCafeASX up 0.58% at noon after Fed comments of decreasing inflation by Peter Milios   The ASX has increased 0.58 per cent at noon, as Wall Street gained following Federal Reserve Chairman Jerome Powell’s comments that financial conditi...

Imugene (IMU) advances its phase one metastatic advanced solid tumours study The phase one trial of IMU’s VAXINIA cancer-killing virus has cleared the second cohort in both the intravenous (IV) and intratumoral (IT) arms of the monothera...

Highlights Imugene Limited’s Phase 1 MAST study has cleared cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial. The company will now commence cohort 1 of the combination study (with Pembrolizumab)...

02 Feb 2023 - A snapshot of the stocks on the move featuring Splitit (ASX:SPT), European Metals Holdings (ASX:EMH) and Alchemy Resources (ASX:ALY).

ShareCafeStocks of the Hour: SPT, EMH, IMU, ALY                    Buy Now Pay Later platform, Splitit (ASX:SPT), has signed a partnership agreement with Ingenico, to create the first one-touch instalment solution embedded into physic...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Highlights A new 100-day high for ASX 200 was noted at market close on 1 February 2023. The ASX 200 was up, gaining 0.33% to 7,501.70. Over the past five days, ASX 200 has gained 0.45%. Top performers of the day included Flight Centr...

The S&P/ASX 200 Index (ASX: XJO) shot to a nine-month high of 7,537.7 points today. However, by the time the market closed it was sitting at 7,501.7 points – marking a 0.33% gain. And leading the way was the S&P/ASX 200 Real Esta...

The share market cruised to a fresh nine-month high after Wall Street rallied into tonight’s interest rate decision. The S&P/ASX 200 put on as much as 61 points in early action before paring its rise to 25 points or 0.33 per cent. To...

The share market recovery of 2023 got back on track as a first rise in three sessions lifted the S&P/ASX 200 to a fresh nine-month high. The Australian benchmark rose to within 1.3 per cent of its 2021 record before trimming its clim...

ShareCafeAus shares close 0.07% lower but rise 6.2% in January by Peter Milios   Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks...

ShareCafeHigh cost of living causes a fall in retail sales: ASX up 0.22% at noon by Peter Milios   Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the...

Imugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer patients During the three months to December 31, 2022 the company saw its first patient dosed in VAXINIA intravenous (IV) cohort two...

The ASX ended Friday flattish, but is at a 9-month high Energy and Miners led today after a series of announcements by majors Chinese lunar New Year ahead   The ASX 200 edged 0.20% higher on Friday, pushing the index to a 9-month high. Fo...

The share market rose to a fresh nine-month high as strength in resource stocks helped offset weak leads from Wall Street. The S&P/ASX 200 continued to test levels last seen in April despite a third straight losing night in the US. T...

Highlights Imugene Limited’s HER-Vaxx and CF33 technologies being presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco. At the event, Imugene got featured in three sessions, namely Oral Abstract Session, Trials in...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The S&P/ASX 200 Index (ASX: XJO) soared to its highest point in nine months on Thursday, peaking at 7439.7 points before slipping slightly to close 0.57% higher at 7,435.3 points. That was despite a poor session on Wall Street overnigh...

The ASX closed flat on Wednesday Local investors are closely watching earnings reports in both the US and Australia EU to release inflation report tonight   The ASX 200 was subdued on Wednesday as investors weighed earnings results in the...

The ASX finally snapped after a 4-day winning streak China’s GDP grew more than expected Miners were sold, Discretionary stocks bought   The ASX 200’s string of wins has been broken today as the index retreated by 0.15%. Traders cautiousl...

The S&P/ASX 200 Index (ASX: XJO) kicked off the week strong, leaping 0.82% on Monday to close at 7,388.2 points. That was despite a lacklustre performance from mining shares. The S&P/ASX 200 Materials Index (ASX: XMJ) lifted just 0...

Optimism about China reopening and hopes for a slowdown in interest rate hikes fuelled the share market’s best week in two months. The S&P/ASX 200 climbed 48 points or 0.66 per cent today to extend its tally for the week to almost 3....

The ASX has had a big first two weeks, rising by over 4% Investors are bullish as inflation looks to have peaked in the US and Europe Earnings season will be next test for the markets   The ASX 200 rose another 0.70% higher on Friday, ext...

A seventh rise in eight sessions powered the share market to its highest in more than a month after Wall Street welcomed further evidence of inflation cooling. The S&P/ASX 200 rallied 63 points or 0.87 per cent to 7344. A strong star...

There was likely a spring in the step of S&P/ASX 200 Index (ASX: XJO) investors today as the market jumped higher. The index closed Thursday’s session 1.18% higher at 7,280.4 points. It followed a joyous session on Wall Street overni...

The ASX surged by another 1% on Thursday The all crucial US CPI will be released later today (US time) ASX lithium stocks rallied   The ASX 200 rallied by yet another 1% on Thursday, closely tracking the bullish sentiment on Wall Street o...

Record retail sales helped the share market brush off the prospect of further interest rate hikes this year after inflation rebounded more than expected. The S&P/ASX 200 climbed 69 points or 0.96 per cent towards its fifth gain in si...

The ASX down by 0.30% on Tuesday Iron ore miners pare gains as China clamps down on speculation Jerome Powell will speak tonight   The ASX 200 lost 0.30% on Tuesday as the biggest three sectors – Energy, Mining and Financial – took a tumb...

ShareCafeAlmost all sectors lower despite signs of optimism in the US: ASX down 0.3% at noon by Peter Milios   Overnight Chris Zaccarelli, Chief Investing Officer at the Independent Advisor Alliance, stated, “Today is another one of those d...

Market goes out too hard, too early and beds down for a lengthy afternoon snooze Tempus Resources still riding high after drilling into phenomenally good gold grades Betting is now open on how long until the ASX’s next “how to announce stu...

The ASX rose in a broad brushed rally Fortescue’s CFO of 13 years quit Australian and US CPI will be due for release later this week   The ASX extended gains in a broad brushed rally on Monday, with 9 out of 11 sectors finishing in the gr...

The share market sealed its longest win run since early November with a fourth straight rise following strong gains on Wall Street as buyers bet on a soft landing for the US economy. The S&P/ASX 200 trimmed its advance as iron ore pr...

Highlights Imugene Limited (ASX:IMU) marked 2022 with breakthrough developments in its clinical studies, progressing to build a deep clinical pipeline At present, IMU has five ongoing clinical trials. However, a total of nine clinical...

Imugene has now crossed ethics approval off is list, and the way is now clear for clinical trials to begin in Australia. The post Imugene Gains Ethics Approval and Receives 5% Share Bump appeared first on Money Morning Australia.

Aussie shares hit a three-week high amid optimism about cooling inflation and China reopening. The S&P/ASX 200 rallied 44 points or 0.62 per cent by mid-session. The advance put the Australian benchmark on track for a fourth straight...

LBT Innovati0ns engaged by global pharma company, AstraZeneca Volpara nabs $7m plus contracts Imugene receives ethics approval for Vaxinia   LBT to partner with AstraZeneca LBT Innovations (ASX:LBT) surged 22%% this morning after announci...

Highlights Imugene Limited (ASX:IMU) has received human research ethics approval for Phase I human trial of anti-cancer oncolytic virotherapy VAXINIA Tasman Oncology Research, a comprehensive cancer hospital in South Australia, is the...

Imugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of its VAXINIA drug in Australia The approval confirms the company has completed all necessary pre-clinical safety and efficacy...